☝🏼#ESMO26 Targeted therapies: toxicity is not just about the drug — context matters.
💥 Key pearls from @NReguart:
• PD-(L)1 → osimertinib: severe irAEs 15%; G≥3 pneumonitis 10%
• PD-(L)1 → sotorasib: G≥3 hepatotoxicity strongly ↑ with short washout
• KRASi + IO: feasible, but toxicity varies markedly across agents
• Dose modification is not = treatment failure
@OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma
79 views · 2 likes · 2 reposts · 0 replies
FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem)
https://esmocongress.esmo.orgPACE-LUNG: A multicenter, single-arm, phase II clinical trial evaluating the efficacy of additional chemotherapy for patients with EGFRm NSCLC with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line
https://esmocongress.esmo.orgSource: Mario Balsa · x.com